An interventional study of Usual Care Group and More Support and Tools in Ethics, Cardiac Rehabilitation and Coronary Heart Disease (CHD), sponsored by Baystate Medical Center. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-30.
Sponsored by Baystate Medical Center · Not applicable, Interventional, and Health services research
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 274 studies in Coronary Disease with a site in United States — 12 open to participants now, 23 under way, 2 of them phase 3. Coronary Disease · United States.
Among the 274 studies in Coronary Disease with a site in United States, this one is the 103rd largest by planned enrollment of the 184 interventional ones that give a count, is one of 4 that started in 2025, is one of 78 with no phase, reaches primary completion later than 2 of the 22 other live ones, and was the 272nd registered.
1,522 studies on the registry are indexed under Coronary Disease; 167 are open to participants now.
Browse Coronary Disease studies →12 of the 274 studies in Coronary Disease with a site in United States are open now. Recruiting first, the newest first:
Teleflex · Sites in United States, France, Latvia and 1 more country
Ages 18–80
Amgen · Sites in United States, Australia, Canada and 1 more country
Ages 50–105
West Virginia School of Osteopathic Medicine · Sites in United States
Ages 18–64
University of California, Los Angeles · Sites in United States
Ages 60–80
Weill Medical College of Cornell University · Sites in United States, Austria, Canada and 3 more countries
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 106 Coronary Disease studies recruiting now, 64 (60%) set no upper age limit and 19 (18%) stop at 75 or younger; 8 take children under 18; 10 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
274 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 15 · Phase 2 43 · Phase 3 36 · Phase 4 18
First in 1973; this study’s year is marked. 4 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 160 is close to the median of 160 across 780 interventional studies indexed under Coronary Disease.
Median enrollment 200 across the 184 interventional studies, 324 across the 87 observational. Of the 235 that completed or were terminated, 88 (37%) have results posted.
This tab as a report to print or save as PDF → With an account.
92 of 274 have an industry lead sponsor. The 10 most frequent:
Baystate Medical Center is the lead sponsor of 48 studies on the registry; 7 are open to participants now.
Baystate Medical Center has 2 studies filed under Coronary Disease — fewer than ten, so there is no comparison to draw.
10 of the studies in Coronary Disease with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05997693Phase 3Weill Medical College of Cornell UniversityOne-Month DAPT in CABG Patients | 2027-01 |
| NCT02694094Johns Hopkins UniversityImpact of Ketogenic Diets on Cardiovascular Health in Adults With Epilepsy | 2026-12 |
| NCT06170541Johns Hopkins UniversityCORE-COMPARE Pilot Study | 2026-12 |
| NCT05918380University Hospitals Cleveland Medical CenterProject 3: ACHIEVE- CHD | 2027-01-01 |
| NCT00406185Intermountain Health Care, Inc.Database Registry of the Intermountain Heart Collaborative Study | 2027-03 |
Add all 10 to your calendar (.ics) → With an account.
Among the 274 studies in Coronary Disease with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Cardiac Rehabilitation is a lifestyle and exercise program for patients with heart disease. Cardiac Rehabilitation is strongly recommended in guidelines, but only 30% of eligible patients attend.
New strategies are needed to help more patients attend cardiac rehabilitation. In this study, the investigators will see if using an $50 incentive, case management, text messages, and physical activity coaching combined into a single intervention will help more patients attend cardiac rehabilitation.
In preparation for a larger trial, patients will also be randomly assigned to four different ways of seeking their permission to be in a research study. The investigators will see if these approaches affect how many people participate in the research project.
The two main goals of this study is to understand:
Cardiac Rehabilitation (CR) is a guideline-recommended therapy that helps patients improve their health and longevity. It is underused, especially among older, sicker, and minority populations. Guidelines make strong recommendations for use among all patients, and there are ongoing national initiatives to improve utilization. At Baystate, cardiac rehabilitation attendance rates are improving, but investigators are still seeking additional strategies to further encourage participation. If the investigators succeed, patients will live longer, healthier lives, thus embodying beneficence.
However, the typical 10-12 page consent form is a major barrier to successful study completion with participation rates in typical clinical trials of 20% of eligible patients. More importantly, it introduces an important selection bias in the population by finding patients who are more responsive to interventions. It also shifts the population towards patients away from underrepresented minorities and yields results that are less applicable to real-world settings with clinical populations. In short, this selection bias is inconsistent with the ethical principle of justice, which states that the same population that is expected to benefit from the research should also be the population that bears the burden of the research. Thus, alternate forms of informed consent are needed to assure a representative population and scientific results that can be confidently generalized.
First, to address issues of consent, the investigators will determine the impact of four different ethical approaches to consent (full consent with signature, 3-page summary consent with signature, 1-page opt-out waiver - no signature, or Non-Consenting (NC) cohort - where patients can refuse any intervention) on study enrollment rate and population representativeness.
Second, the investigators will assess the feasibility and utilization of a multi-dimensional intervention to increase CR enrollment. These will include combining a financial incentive, case management, text messaging program, and physical activity coaching, all with the goal of increasing CR enrollment. The investigators will assess the acceptance rate of intervention components and the overall feasibility of the proposed intervention in preparation for larger clinical trials.
Patients will be randomized to 1 of 4 consent approaches shown below. All consent documents and corresponding waivers were submitted to a full board IRB and approved.
Patients who agree to participate by signing a consent form, by not opting out, or by being randomized to the non-consent group will be re-randomized to either the Usual Care or MOST group. Additional details of these interventions are found below.
If patients consent, do not opt-out, or are randomized to the non-consenting cohort, they will be re-randomized 1:1 to either usual care or a multifactorial CR intervention. This intervention will include four components: financial incentives, text messaging, case management, and physical activity coaching, combined as a single intervention.
The primary outcome will be the proportion of patients (%) participating in the clinical trial. The secondary outcome will be enrollment in CR within 3 months of hospital discharge.
All interventions are minimal risk. They are typically found in routine clinical medicine and have been used without difficulty in other settings. In any group, patients can refuse any or all components of the intervention, thus respecting patient autonomy. If patients respond and attend CR, they will gain health benefits, which is consistent with the ethical principle of beneficence.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
- Patients with coronary artery bypass graft surgery, heart valve surgery, or other open-heart surgical procedures will be excluded, as these patients are much more likely attend CR, typically around 70%. In addition, patients who are referred to CR programs outside the region, where enrollment cannot be tracked, will be excluded.
Standard Consent approach (typically 10-12 pages)
Behavioral: Usual Care Group · Behavioral: More Support and Tools
Three page key Information consent
Behavioral: Usual Care Group · Behavioral: More Support and Tools
1 page opt-out consent approach
Behavioral: Usual Care Group · Behavioral: More Support and Tools
No consent
Behavioral: Usual Care Group · Behavioral: More Support and Tools
Standard of care to encourage cardiac rehabilitation attendance.
More Support and Tools includes the following: monetary incentive, text messages, case management, and physical activity coaching. The investigators will start providing support and tools while patients are still in the hospital and continue this support weekly after discharge. Intervention participants will receive a monetary incentive both in the hospital and upon attending cardiac rehabilitation. The support (case management) and tools (physical activity coaching and text messages) will continue for up to 3 months or until the individual attends cardiac rehabilitation, whichever occurs first. Participants can decline any or all support or tools.
Informed Consent Approach Participation
The proportion of patients (%) participating in the clinical trial.
Time frame: Baseline
Cardiac Rehabilitation Attendance
The proportion (%) of patients who attend 1 or more sessions of cardiac rehabilitation
Time frame: Up to to 3 months after hospital discharge, or cardiac rehabilitation attendance, whichever comes first.
Age Representativeness of Consenting Groups
Each consent group will be analyzed based on the demographics of patients participating. The age characteristics of each consent group will be measured in years.
Time frame: Baseline
Sex Representativeness of Consenting Groups
Each consent group will be analyzed based on the demographics of patients participating. The sex characteristics of each consent group will be measured as male, female, or other.
Time frame: Baseline
Race Representativeness of Consenting Groups
Each consent group will be analyzed based on the demographics of patients participating. The race characteristics of each consent group will be measured using the five NIH racial categories (American Indian or Alaska Native, Asian, Black or African American, Native Hawaiian or Other Pacific Islander, and White).
Time frame: Baseline
Ethnicity Representativeness of Consenting Groups
Each consent group will be analyzed based on the demographics of patients participating. The ethnicity characteristic of each consent group will be measured using the NIH defined categories (Hispanic or Latino, and Not Hispanic or Latino).
Time frame: Baseline
Cardiac Rehabilitation Qualifying Diagnosis Representativeness of Consenting Groups
Each consent group will be analyzed based on the demographics of patients participating. The cardiac rehabilitation qualifying diagnosis characteristic of each consent will be measured.
Time frame: Baseline
The Porportion of Intervention Accepted
The proportion of patients (%) who accept each intervention (financial incentives, case management, physical activity coaching, and text messaging) will be measured.
Time frame: Up to to 3 months after hospital discharge, or cardiac rehabilitation attendance, whichever comes first
Plan to share: Undecided — De-identified individual data may be shared, but given that patients are randomized to 4 different informed consent approaches, one of which is a non-consent group, it is unclear if the Institutional Review Board (IRB) would allow data sharing. At this time, data sharing seems unlikely.
No publications or documents are linked to this record.
Ran from Jul 2025 to primary completion in Sep 2025, 1 month.
Of 180 non-industry interventional studies with no phase under Coronary Disease, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 51. This study's 1 month is below that.
Counting every sponsor, half of 202 studies reached it within 25 months; a quarter within 14 and three quarters within 51.
Since we started tracking on Sep 25, 2026, the dates moved once, on Sep 30, 2026: primary completion Jan 2026 → Sep 2025 and completion Jun 2026 → Mar 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Baystate Medical Center